CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

328

Participants

Timeline

Start Date

October 19, 2017

Primary Completion Date

May 22, 2018

Study Completion Date

June 20, 2018

Conditions
Dry Eye Disease
Interventions
DRUG

CyclASol topical ocular, eye drops

Cyclosporine A solution in vehicle

DRUG

Vehicle topical ocular, eye drops

Vehicle

Trial Locations (9)

23502

CYS-003 Investigational Site, Norfolk

37205

CYS-003 Investigational Site, Nashville

38119

CYS-003 Investigational Site, Memphis

40206

CYS-003 Investigational Site, Louisville

46290

CYS-003 Investigational Site, Indianapolis

90505

CYS-003 Investigational Site, Torrance

92663

CYS-003 Investigational Site, Newport Beach

01810

CYS-003 Investigational Site, Andover

02767

CYS-003 Investigational Site, Raynham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novaliq GmbH

INDUSTRY

NCT03292809 - CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) | Biotech Hunter | Biotech Hunter